Stockscreener 앱 받기
4.17
2.96%
0.12
시간 외 거래:
4.29
0.12
+2.88%
전일 마감가:
$4.05
열려 있는:
$4.01
하루 거래량:
259.14K
Relative Volume:
0.45
시가총액:
$364.61M
수익:
$33.98M
순이익/손실:
$-95.10M
주가수익비율:
-0.4167
EPS:
-10.0072
순현금흐름:
$-106.13M
1주 성능:
+7.47%
1개월 성능:
+34.52%
6개월 성능:
+31.55%
1년 성능:
-53.60%
1일 변동 폭
$3.92
$4.175
1주일 범위
$3.53
$4.42
52주 변동 폭
$1.35
$9.564
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.17 | 354.12M | 33.98M | -95.10M | -106.13M | -10.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | Guggenheim | Buy |
| 2025-12-05 | 재개 | Stifel | Buy |
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail
Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results - MarketBeat
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10TV
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) cuts costs, raises cash to advance mavorixafor - Stock Titan
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Aug Sectors: Is X4 Pharmaceuticals Inc impacted by rising ratesPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
X4 Pharmaceuticals Inc (XFOR) Stock News & Articles - 24/7 Wall St.
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now? - TradingView
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology - Investing.com
Amphastar (AMPH) CEO logs 10,850-share RSU tax withholding, retains large stake - Stock Titan
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Summary: Is X4 Pharmaceuticals Inc impacted by rising ratesTrade Analysis Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Guggenheim initiates X4 Pharmaceuticals stock with buy rating - Investing.com Australia
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - Yahoo Finance
Xenon Pharmaceuticals to Announce Topline Data from Phase 3 X-TOLE2 Study of Azetukalner for Focal Onset Seizures - Quiver Quantitative
Phase 3 seizure drug data Monday in Xenon focal onset study - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Can X4 Pharmaceuticals Inc lead its sector in growthJuly 2025 Reactions & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Morgan Stanley, MSIM report stakes in X4 Pharmaceuticals (NASDAQ: XFOR) - Stock Titan
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - The Manila Times
XFOR Technical Analysis & Stock Price Forecast - Intellectia AI
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
XFOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
Biotech X4 hires staff with stock options priced at $3.44 - Stock Titan
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):